Challenges of cell therapies for retinal diseases.

Animals Humans Cell- and Tissue-Based Therapy Retinal Degeneration / therapy Mammals
Age-related macular degeneration Cell therapy Human pluripotent stem cells Retinitis pigmentosa Retinopathies

Journal

International review of neurobiology
ISSN: 2162-5514
Titre abrégé: Int Rev Neurobiol
Pays: United States
ID NLM: 0374740

Informations de publication

Date de publication:
2022
Historique:
entrez: 24 11 2022
pubmed: 25 11 2022
medline: 29 11 2022
Statut: ppublish

Résumé

Because retinal cells could not regenerate in mammals, retinal degeneration is an irreversible phenomenon caused by various disease conditions including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). During the course of these diseases, photoreceptors (PRs) are susceptible to degenerate due to their malfunctions or to a primary dysfunction of the retinal pigment epithelium (RPE). These diseases affect millions of individuals worldwide. Many therapies currently under development are designed to treat retinal pathologies and among those, cell-based replacement strategies hold significant promise for treatment of retinal degenerative diseases, especially when atrophy of retinal tissue occurs. This review will focus on the use of hPSCs to slow-down or treat retinal disorders and discuss current challenges to achieve successful engraftment of cell products.

Identifiants

DOI: 10.1016/bs.irn.2022.09.004 PMID: 36424096
pubmed: 36424096
pii: S0074-7742(22)00095-2
doi: 10.1016/bs.irn.2022.09.004
pii:
doi:

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-77

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Monville Christelle (M)

INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases, Corbeil-Essonnes, France; Paris Saclay Evry U861, Corbeil-Essonnes, France. Electronic address: cmonville@istem.fr.

Morizur Lise (M)

INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases, Corbeil-Essonnes, France; Paris Saclay Evry U861, Corbeil-Essonnes, France; CECS, Corbeil-Essonnes, France.

Karim Ben M'Barek (K)

INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases, Corbeil-Essonnes, France; Paris Saclay Evry U861, Corbeil-Essonnes, France; CECS, Corbeil-Essonnes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Challenges of cell therapies for retinal diseases.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Challenges of cell therapies for retinal diseases.
questionsmedicales.fr › Thérapeutique › Biothérapie › Thérapie cellulaire et tissulaire › Challenges of cell therapies for retinal diseases.
questionsmedicales.fr › Maladies de l'oeil › Rétinopathies › Dégénérescence de la rétine › Challenges of cell therapies for retinal diseases.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Challenges of cell therapies for retinal diseases.